Results 151 to 160 of about 16,217 (195)
Some of the next articles are maybe not open access.
Biotechnology Letters, 2020
Programmed death ligand 1 (PDL1, CD274, B7-H1) has been identified as the ligand for the immune inhibitory receptor programmed death 1 protein (PD1/PDCD1). PDL1 is a member of B7 family of immune molecules and this protein together with PDL2, are two ligands for PD1 expressed on activated lymphoid cells. By binding to PD1 on activated T cells, PDL1 may
Shufeng Li +6 more
openaire +2 more sources
Programmed death ligand 1 (PDL1, CD274, B7-H1) has been identified as the ligand for the immune inhibitory receptor programmed death 1 protein (PD1/PDCD1). PDL1 is a member of B7 family of immune molecules and this protein together with PDL2, are two ligands for PD1 expressed on activated lymphoid cells. By binding to PD1 on activated T cells, PDL1 may
Shufeng Li +6 more
openaire +2 more sources
Nanobodies: new avenue to treat kidney disease
Cell and Tissue Research, 2021 Current therapeutic options for renal diseases are limited, and the search for disease-specific treatments is ongoing. Nanobodies, single-domain antibodies with many advantages over conventional antibodies, provide flexible, easy-to-format biologicals ...
Nicola Wanner +2 more
exaly +2 more sources
Nanobodies and Their Potential Applications
Nanomedicine, 2013Nanobodies are recombinant, antigen-specific, single-domain, variable fragments of camelid heavy chain-only antibodies. The innate supremacy of nanobodies as a renewable source of affinity reagents, together with their high production yield in a broad variety of expression systems, minimal size, great stability, reversible refolding and outstanding ...
Gholamreza Hassanzadeh-Ghassabeh +4 more
openaire +3 more sources
Science Signaling
Antibody fragments can act as pharmacological tools to modulate the functions of G protein–coupled receptors.
openaire +2 more sources
Antibody fragments can act as pharmacological tools to modulate the functions of G protein–coupled receptors.
openaire +2 more sources
Trends in nanobody radiotheranostics
European Journal of Nuclear Medicine and Molecular ImagingAs the smallest antibody fragment with specific binding affinity, nanobody-based nuclear medicine has demonstrated significant potential to revolutionize the field of precision medicine, supported by burgeoning preclinical investigations and accumulating clinical evidence.
Xingru Long +4 more
openaire +2 more sources
Nanobody-Based Chromatin Immunoprecipitation
2012Chromatin immunoprecipitation (ChIP), followed by microarray hybridization (ChIP-chip) or high-throughput sequencing (ChIP-seq), is becoming a widely used powerful method for the analysis of the in vivo DNA-protein interactions at genomic scale.The success of ChIP largely depends on the quality of antibodies.
NGUYEN DUC, Trong +5 more
openaire +3 more sources
Optogenetic Activation of Intracellular Nanobodies
2022Intracellular antibody fragments such as nanobodies and scFvs are powerful tools for imaging and for modulating and neutralizing endogenous target proteins. Optogenetically activated intracellular antibodies (optobodies) constitute a light-inducible system to directly control intrabody activities in cells, with greater spatial and temporal resolution ...
Daseuli, Yu, Heo, Won Do
openaire +2 more sources